Overview
Using Implementation Science to Reduce the Impact of RSV Disease on Infants, Families, and the Healthcare System
Click the "Start Activity" button to indicate you have reviewed the CME/CE information for this activity.
Start Activity
Each year, respiratory syncytial virus (RSV) leads to over 2 million outpatient visits, up to 80,000 hospitalizations, and as many as 300 deaths among children younger than age 5. And, while prematurity and certain health problems increase the risk for severe RSV infection, most children hospitalized for RSV in the United States have no underlying health conditions or history of preterm birth. Available guidance recommends that clinicians provide RSV prophylaxis to all infants aged <8 months during their first RSV season and to high-risk children during their second season. The availability of novel preventive approaches and new guidance, as well as the recent approval of a maternal RSV vaccine, has created questions amongst clinicians. To answer these questions, this activity offers synergistic education and practical guidance to easily incorporate into routine clinical decision-making processes.
This educational activity is designed for pediatricians, family practice physicians, NPs and PAs in these settings, neonatologists, and other HCPs who support preventive health practices in children. Other clinicians who may benefit from this education include neonatologists, obstetricians, and midwives.
Respiratory syncytial virus (RSV) is a common pathogen that infects nearly all children by the age of 2 years. Seasonal epidemics place substantial pressure on healthcare systems with an increased number of emergency department visits and hospitalizations. There is also a potential for long-term sequelae such as wheezing and post-bronchiolitis reactive airway disease. Preventive therapeutic options for pediatric RSV were previously limited; however, there is now an approved long-acting monoclonal antibody with others under investigation as well as a vaccine administered during pregnancy to protect infants. The diversity of available and emerging RSV prevention strategies may challenge pediatric clinicians to stay abreast of available data and guideline recommendations. As such, education on the changing RSV epidemiology, identification of patients most at risk for RSV, and practical application of therapies for prevention of pediatric RSV is needed.
Upon completion of this activity, learners will be able to:
• Review RSV prevalence and associated lower respiratory tract infections and hospitalizations in infants.
• Identify protective factors and risk factors for RSV development in infants.
• Evaluate safety and efficacy data of novel long-acting monoclonal antibody therapies for the prevention of pediatric RSV.
• Introduce system-based practices to mitigate the impact of RSV disease.
• Review RSV prevalence and associated lower respiratory tract infections and hospitalizations in infants.
• Identify protective factors and risk factors for RSV development in infants.
• Evaluate safety and efficacy data of novel long-acting monoclonal antibody therapies for the prevention of pediatric RSV.
• Introduce system-based practices to mitigate the impact of RSV disease.
Provided by the Academy for Continued Healthcare Learning (ACHL).
Supported by an educational grant from Sanofi US.
Joseph Domachowske, MD, FAAP, FPIDS
Professor of Pediatrics
Professor of Microbiology and Immunology
Department of Pediatrics
SUNY Upstate Medical University
Syracuse, NY
Professor of Pediatrics
Professor of Microbiology and Immunology
Department of Pediatrics
SUNY Upstate Medical University
Syracuse, NY
Tina Q. Tan, MD, FAAP, FIDSA, FPIDS
Professor of Pediatrics
Feinberg School of Medicine, Northwestern University
Infectious Diseases Attending Physician
Medical Director, International Patient and Destination Services Program
Vice President, Lurie Medical/Dental Staff
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, IL
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with all ineligible companies. All relevant financial relationships have been mitigated prior to this activity.
The following financial relationships have been provided:
Joseph Domachowske, MD, FAAP, FPIDS
Grants/Research: Glaxo Smith Kline, Moderna, Pfizer, Sanofi
Consultant (occasional): Glaxo Smith Kline, Moderna, Sanofi
Consultant (retained): Shionogi, Inc.
Tina Q. Tan, M.D., FAAP, FIDSA, FPIDS
Vaccine Advisory Board: Glaxo Smith Kline, Merck, Moderna, Pfizer, Sanofi Pasteur
Sources of Funding for Research: Glaxo Smith Kline
Consulting Agreements: Pfizer,Sanofi Pasteur
Discussion of scientific information on unapproved uses (SIUU), off-label, investigational, or experimental drug/device use: Additional monoclonal antibodies under investigation for prevention of RSV
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of any ineligible company. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor(s).
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 60 minutes to complete. To receive credit, learners are required to complete the pretest, view the online activity, and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physician assistants, nurse practitioners, and nurses may participate in this educational activity and earn a certificate of completion as AAPA, AANP, and ANCC accept AMA PRA Category 1 Credits™ through their reciprocity agreements.
